Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
10- 10.2Pre-market26.10.02 20:308-KKey event#●●●#●●●
CERENOME, INC.
Cerenome, Inc. updated its corporate presentation as of September 30, 2026, highlighting the commercial progress and growth strategy for its CNS cancer diagnostic and therapeutic platforms. The company reported that 24 institutions have adopted its CNSide diagnostic platform with increasing commercial orders, and it is targeting revenue growth through a Medicare rate effective January 1, 2027, and the deployment of a field sales team in Q4 2026.…more
$1.65-0.90%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.1Pre-market26.10.01 21:004Ownership
CERENOME, INC.
Insider An van Es-Johansson of CERENOME, INC. filed a Form 4 on October 1, 2026, reporting a change in beneficial ownership of securities. This filing reflects the updated holdings of the reporting insider.…more
$1.65-0.90%vs prev closeView filingShare - 10.1Pre-market26.10.01 21:004Ownership
CERENOME, INC.
Insider Richard J. Hawkins of CERENOME, INC. filed a Form 4 on October 1, 2026, regarding changes in beneficial ownership of securities. This filing serves as a standard report of insider equity transactions.…more
$1.65-0.90%vs prev closeView filingShare
9 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoPre-market26.10.21 20:31#●●●#●●●
Cerenome Presents New Preclinical Data for Ovarian Cancer Drug REYOBIQ
Cerenome announced new preclinical data demonstrating the immunomodulatory properties of its lead radiotherapeutic, REYOBIQ. The study showed tumor reduction in mouse models and enhanced antitumor activity when combined with anti-PD-1 therapy.…more
$1.65-0.90%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 4d agoPre-market26.10.21 20:30
●●●●●●●● ●●●●● ●●●●●●
Cerenome announced preclinical data showing its radiotherapeutic candidate REYOBIQ improves the tumor microenvironment and enhances immune response in ovarian cancer models. While the findings suggest potential for combination therapy with checkpoint inhibitors, the results are based on early-stage research.…more
$1.65-0.90%vs prev close - 10.8Pre-market26.10.08 20:30
●●●●●●●● ●●●●● ●●●●●●
Cerenome has entered into an in-network agreement with Florida Blue to provide insurance coverage for its CNSide tumor cell and molecular profile tests. This partnership expands the company's payer footprint and supports the commercial rollout of its integrated diagnostic platform.…more
$1.65-0.90%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report